

Vinson & Elkins
ATTORNEYS AT LAW



#2

May 1, 2002

VINSON & ELKINS L.L.P.
2300 FIRST CITY TOWER
1001 FANNIN STREET
HOUSTON, TEXAS 77002-6760
TELEPHONE (713) 758-2222
FAX (713) 758-2346
www.velaw.com

Margaret J. Sampson
Direct Dial (512) 495-8569
Direct Fax (512) 236-3264
msampson@velaw.com

CERTIFICATE OF MAILING

I, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents; Washington, D.C. 20231 on the date below:

May 1, 2002
Date

Margaret J. Sampson
Margaret J. Sampson

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 10/067,076 entitled "*Genetic Marker for Autoimmune Disorder*" by Carol A. Wise (Atty. Docket No. TEX871/36000/4-006US)

Sir:

Enclosed for filing in the above-referenced patent application is:

1. An Information Disclosure Statement;
2. PTO Form 1449;
3. A copy of reference C20; and
4. A return postcard to acknowledge receipt of these documents. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from VINSON & ELKINS L.L.P. Deposit Account No. 22-0365/TEX871/4-006US.

Respectfully submitted,

Margaret J. Sampson
Reg. No. 47,052

1864:3058
Enclosures
278943_1.DOC

Assistant Commissioner for Patents

Page 2

May 1, 2002

bcc: Kimberley Simpson (w/encl.)
Marya Breig, Docketing Specialist (w/o encl.)
Bobbie Melder, Docketing Specialist (w/o encl.)



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Carol A. Wise

Serial No.: 10/067,076

Filed: February 4, 2002

For: GENETIC MARKER FOR
AUTOIMMUNE DISORDER

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: TEX871/4-006US

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

May 1, 2002
Date

Margaret J. Sampson
Margaret J. Sampson

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record. Only one copy of Reference C20 as required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner. The additional references (C1-C19) were previously submitted to the USPTO in an Information Disclosure Statement and Supplemental Information Disclosure Statement filed March 15, 2001 and April 9, 2001, respectively, for U.S. Patent Application No. 09/710,693, to which the current application claims priority.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Vinson & Elkins L.L.P. Deposit Account No. 22-0365/TEX871/4-006US.


Respectfully submitted,



Margaret J. Sampson
Reg. No. 47,052
Attorney for Applicant

Vinson & Elkins L.L.P.
2300 First City Tower
1001 Fannin Street
Houston, Texas 77002-6760
512/495-8569

Date: May 1, 2002
278949_1.DOC

**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*

Docket Number (Optional)

TEX871/4-006US

Application Number

10/067,076

Applicant(s)

Carol A. Wise

Filing Date

February 4, 2002

Group Art Unit

Unknown**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Dowbenko et al., "Identification of a Novel Polyproline Recognition Site in the Cytoskeletal Associated Protein, Proline Serine Threonine Phosphatase Interacting Protein," Journal of Biol. Chem., 273(2):989-96, 1998
	C2	Heward and Gough, "Genetic susceptibility to the development of autoimmune disease," Clinical Science 93:479-91, 1997
	C3	Jacobs and Goetzl, "'Streaking Leukocyte Factor,' Arthritis, and Pyoderma Gangrenosum", Pediatrics, 56(4)570-78, 1975
	C4	Kammerer, et al., "Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation," Eur. J. Immunol. 28:3664-74, 1998
	C5	Li, et al., "A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion," The EMBO Journal, 17(24):7320-36, 1998
	C6	Lindor, et al., "A New Autosomal Dominant Disorder of Pyogenic Sterile Arthritis, Pyoderma Gangrenosum, and Acne: PAPA Syndrome," Mayo Clin. Proc. 72:611-15, 1997

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Docket Number (Optional) TEX871/4-006US		Application Number 10/067,076
Applicant(s) Carol A. Wise		
Filing Date February 4, 2002	Group Art Unit Unknown	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C7	Lucka, et al., "Carcinoembryonic antigen-related cell-cell adhesion molecule C-CAM is greatly increased in serum and urine of rats with liver diseases," FEBS Letters 438:37-40, 1998
	C8	Moroldo, et al., "Transmission Disequilibrium as a Test of Linkage and Association between HLA Alleles and Pauciarticular-Onset Juvenile Rheumatoid Arthritis," Arthritis & Rheumatism 41(9):1620-24, 1998
	C9	Murray, et al., "Pathogenesis of juvenile chronic arthritis: genetic and environmental factors," Archives of Disease in Childhood 77:530-34, 1997
	C10	Rossen, et al., "Linkage of HLA to Disease Susceptibility Locus in Four Families where Proband Presented with Juvenile Rheumatoid Arthritis," J. Clin. Invest. 65:629-42, 1980
	C11	Rossen, et al., "Familial Rheumatoid Arthritis: A Kindred Identified Through a Proband with Seronegative Juvenile Arthritis Includes Members with Seropositive, Adult-Onset Disease," Human Immunology, 4:183-96, 1982
	C12	Spencer, et al., "PSTPIP: A Tyrosine Phosphorylated Cleavage Furrow-associated Protein that Is a Substrate for a PEST Tyrosine Phosphatase," Journal of Cell Biology, 138(4):845-60, 1997
	C13	Stocks, et al., "Expression of the CD 15 differentiation antigen (3-fucosyl-N-acetyl-lactosamine, Lex) on putative neutrophil adhesion molecules CR3 and NCA-160," Biochem. J. 268:275-80, 1990
	C14	Stocks and Kerr, "Stimulation of neutrophil adhesion by antibodies recognizing CD15(LeX) and CD15-expressing carcinoembryonic antigen-related glycoprotein NCA-160," Biochem. J. 288:23-27, 1992
	C15	Vyse and Todd, "Genetic Analysis of Autoimmune Disease," Cell, 85:311-18, 1996
	C16	Warren, et al., "A Carbohydrate Structure Associated with CD15 (Lewis-x) on Myeloid Cells Is a Novel Ligand for Human CD2," J.Immunology, 156:2866-73, 1996

